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Summary N-1-leucyl-doxorubicin and vinblastine-isoleucinate can be considered as relatively non-toxic
prodrugs from doxorubicin and vinblastine, respectively. A comparative analysis was carried out of the
anti-tumour activity of the four compounds as well as vintriptol in four human ovarian cancer xenografts
different in histology, growth rate and chemosensitivity. Injections were given i.v. weekly twice into mice
bearing well-established s.c. tumours. At equitoxic doses, the amount of drug administered for N-l-leucyl-
doxorubicin and vinblastine-isoleucinate was respectively 3-fold and 2-fold higher than the doses of the parent
compound. N-l-leucyl-doxorubicin induced a growth inhibition > 50% in three out of four human ovarian
cancer lines. The anti-tumour effects obtained were significantly better (P <0.01) than in the case of
doxorubicin. Vinblastine-isoleucinate studied in two of these lines could induce a growth inhibition of >50%.
This prodrug appeared slightly less effective than vinblastine. Insignificant growth inhibition (<50%) was
obtained by vintriptol.
Several natural products with antitumour activity have found
an important place in the armentarium of anticancer drugs.
Major examples are the glycoside antibiotics doxorubicin and
daunomycin, both isolated from the fungus Streptomyces
peucetius (Young et al., 1981), and the alkaloids vincristine
and vinblastine, both derived from the Madagascan peri-
winkle, Vinca rosea L. (Johnson et al., 1963). Clinical trials
have demonstrated that each compound can be defined for
its optimal schedule of administration, its particular anti-
tumour activity profile and its characteristic side-effects. For
many years, part of the search for new anti-cancer drugs has
been focussed on the synthetic modification of these natural
products to obtain an improved therapeutic index. A few
analogues, such as epirubicin and vindesine, have been incor-
porated into the growing group of conventional cytostatic
agents.
The synthesis of relatively non-toxic prodrugs of conven-
tional cytostatic agents is another approach to limit side-
effects. This concept is based on the conversion of the
prodrug into its active form by an enzyme, which is
preferably exclusive for the target tissue. Theoretically, the
prodrug can be given in large doses enabling high concentra-
tions of free drug available at the tumour site. Several
examples ofprodrugs are found in the purine and pyrimidine
analogues, which substitute for natural nucleotides and
inhibit the formation of nucleic acids. There is evidence, that
these antimetabolites have some selectivity for rapidly divid-
ing cells, but this may reflect the greater metabolic demand
of such cells rather than selective activation (Waller et al.,
1989).
In 1980, the group of Trouet (Baurain et al., 1980; Mas-
quelier et al., 1980a) have selected leucyl-derivatives for fur-
ther preclinical development, because these prodrugs were
most sensitive to enzymatic hydrolysis as compared to other
amino acid derivatives. N-l-leucyl-doxorubicin (leu-doxo-
rubicin) and vinblastine-isoleucinate (vinblastine-leu) are such
products synthesised by a linkage of the parent compound to
a protein carrier enabling release of active drug after
endocytosis by tumour cells or after enzymatic activation in
the pericellular space. We have carried out a comparative
analysis of the growth inhibitory capacity of doxorubicin,
vinblastine, their respective prodrugs as well as vintriptol at
equitoxic doses in human ovarian cancer xenografts grown as
s.c. tumours in nude mice.
Materials and methods
Tumour lines
The human ovarian cancer lines used in the experiments
were: Ov.Pe, a moderately differentiated mucinous adenocar-
cinoma with a mean volume doubling time (TD) of 8 days;
Ov.Sh, a poorly differentiated serous adenocarcinoma with a
TD of 15 days; Ov.Ri(C), a moderately differentiated serous
adenocarcinoma with a TD of 11 days; FKo, a moderately
differentiated serous adenocarcinoma with a TD of 12 days.
Xenografts were grown in female nude mice (Hsd: athymic
nude-nu) purchased from Harlan Cpb, Zeist, The Nether-
lands. The maintenance of the animals and the transplanta-
tion procedure for tumour tissue fragments implanted s.c.
into both flanks have been described before (Boven et al.,
1990).
Treatment and evaluation
All compounds were provided by Medgenix Group, Fleurus,
Belgium. N-l-leucyl-doxorubicin contains one I-leucine amino
acid linked to the amino group of doxorubicin as previously
published for leu-daunomycin (Masquelier et al., 1980a).
The drug was dissolved in water at a concentration of
20 mg ml-l immediately before use. Doxorubicin was dis-
solved in water at a concentration of 2 mg ml-1. Vinblastine-
isoleucinate is a vinblastine-23-oyl amino acid derivative,
which possesses an isoleucinate ethyl ester (Bhushana Rao et
al., 1985). The drug was dissolved in glucose 5% at a
concentration of 2 mg ml-' immediately before use. Vintrip-
tol (4-deacetyl-3-L-ethyltryptophyl vincaleukoblastine
dimethane sulphonate) has a tryptophan ethyl ester linked to
the amino ester of the vinblastine-23-oyl moiety (Bhushana
Rao et al., 1985). This drug was dissolved in glucose 5% at a
concentration of 10mgml- , whereas the concentration of
vinblastine sulphate in glucose 5% was 1 mg ml-'.
The methodology of the therapeutic experiments was
derived from the guidelines reported earlier for preclinical
phase II drug screening in human tumour xenografts (Boven
et al., 1988) and will be briefly described. Xenografts were
measured weekly in three dimensions with a vernier caliper
by the same observer. The volume was calculated by the
equation length x width x thickness x 0.5, and expressed in
mm3. At the start of treatment, groups of five to six tumour-
bearing mice were formed to provide eight to twelve tumours
with a mean volume between 50-150 mm3 in each group. All
drugs were injected i.v. weekly x 2 at the maximum tolerated
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dose (MTD). This dose required a mean weight loss of
10-15% of the initial weight within 2 weeks after the first
injection. Deaths occurring within 2 weeks after the final
injection were considered as toxic deaths; these animals were
excluded from the study.
For evaluation of drug efficacy, the tumour volumes were
converted to values related to the initial tumour volume.
This relative tumour volume was expressed by the formula
VT/VO, where VT is the volume at any given day and Vo the
volume at the start of treatment. The ratio of the mean
relative volume of treated tumours over that of control
tumours multiplied by 100% (T/C%) was assessed on each
day of measurement. From the lowest T/C% obtained within
5 weeks after the last day of injection growth inhibition
(100%-T/C%) was calculated to express drug efficacy. Anti-
tumour effects were evaluated with Student's t-test.
Results
Maximum tolerated doses
In collaboration with other testing laboratories in Europe
coordinated by the EORTC New Drug Development Office
MTDs of the various compounds were determined for week-
ly x 2 i.v. injections in non-tumour-bearing nude mice first.
Various doses were given to groups of4-6 animals each and
mean body weight loss was recorded from daily measure-
ments. If required, the MTD was adjusted in tumour-bearing
mice or in experiments performed in another nude mouse
strain.
Doxorubicin was administered at a dose of 8 mgkg-' as
has been previously published (Boven et al., 1988; Boven et
al., 1990). For leu-doxorubicin it was found that doses of
32-40 mg kg-' induced a mean weight loss of up to 6-7%,
but irreversible cachexia after the third week of treatment
comprised the evaluability of anti-tumour efficacy. This was
reason to reduce the dose to 28 mgkg-' in tumour-bearing
mice, which appeared to be well tolerated.
Doses for vinblastine and vinblastine-leu were 6 mg kg-
and 12 mgkg-1, respectively, which were similar to the
MTDs in other testing laboratories (Hendriks et al., 1992).
However, in our nude mouse strain vintriptol 60 mg kg-'
induced a mean weight loss of 13%, which was 7% at a dose
of 50 mg kg-'. Therefore it was decided to select the
50 mg kg-' dose for the therapeutic experiments, which was
slightly lower than given in other testing laboratories (Hen-
driks et al., 1992).
To give insight in the toxicity in the ultimate experiments
residual weight loss measured at day 14 after the start of
treatment and toxic deaths within two weeks after the last
injection are indicated in Table I. In general, recovery from
weight loss was completed by day 21.
Anti-tumour efficacy
The anti-tumour effects of doxorubicin and leu-doxorubicin
were compared in four human ovarian cancer lines (Table I
and Figure 1). At equitoxic doses, the amount of drug for
leu-doxorubicin administered was 3-fold higher as compared
to the parent compound. In the tumour lines Ov.Pe, Ov.Sh,
and Ov.Ri(C) leu-doxorubicin induced a growth inhibition of
65%, 89% and 76%, respectively. The prodrug was remark-
ably better effective than doxorubicin (P<0.01). Ov.Sh
xenografts were most sensitive for both anthracyclines. No
growth inhibition was obtained in FKo xenografts with any of the drugs.
Vinblastine, vinblastine-leu, and vintriptol were compared for their activity in Ov.Pe and Ov.Sh xenografts (Table I and
Figure 2). At equitoxic doses, the amount of drug for
vinblastine-leu was 2-fold higher than that for the parent compound. With vintriptol, no growth inhibition was
obtained. In contrast, vinblastine was very effective with a
growth inhibition of 84% in Ov.Pe and of 73% in Ov.Sh
xenografts. Vinblastine-leu was clearly effective, but slightly less than vinblastine in both tumour lines. However, this
difference was not significant in Ov.Sh xenografts.
Discussion
Human tumour xenografts in nude mice have been demon-
strated to retain the histological pattern and the chemosen-
sitivity profile ofthe tumour tissue oforigin (Winograd et al., 1987). In the past, we have shown that a panel of human
ovarian cancer xenografts has predictive value for the activity of analogues from conventional cytostatic agents as well as
for investigational drugs in the clinical situation (Boven et
al., 1985a, 1985b, 1990). We found leu-doxorubicin better
effective than doxorubicin, vinblastine-leu was slightly less
effective than vinblastine, and vintriptol was ineffective in the
human ovarian cancer xenografts selected for the present experiments.
Leu-doxorubicin has been shown earlier to have a more
favourable toxicity and anti-tumour activity profile as com-
pared to the parent compound. In this respect, the prodrug did induce less cardiomyopathy after chronic treatment in
rabbits, while 3-3.5 times the doxorubicin dose could be
administered (Jaenke et al., 1980). This reduced car-
diomyopathy appeared attributable to a lower accumulation
ofactive drug in heart tissue, which was also demonstrated in
mice (Deprez-De Campeneere et at., 1982). In L1210 leu-
Table I Growth inhibition obtained with conventional cytostatic agents and prodrugs in
human ovarian cancer xenografts
Tumour Dose Growth in- Weight loss Toxic line Drug mgkg-' hibition (%) Day % ± s.d. deaths
Ov.Pe Doxorubicin 8 43a 35 8 ± 5 0/5
Leu-doxorubicin 28 6sa,b 35 13 ± 5 0/6 Ov.Sh Doxorubicin 8 76a 36 9± 6 0/5
Leu-doxorubicin 28 8ga,b 36 5± 5 0/5 Ov.Ri(C) Doxorubicin 8 59a 28 6± 4 0/6
Leu-doxorubicin 28 76ab 28 13 ± 5 0/6 FKo Doxorubicin 8 0 28 3 ± 4 0/6
Leu-doxorubicin 28 0 28 2± 5 0/6
Ov.Pe Vinblastine 6 84a 28 4± 3 0/6
Vinblastine-leu 12 67a,c 28 2 ± 5 0/6 Vintriptol 50 34a,c 28 3 ± 4 0/6 Ov.Sh Vinblastine 6 73a 35 8 ± 9 1/5
Vinblastine-leu 12 51a 35 11 ± 8 0/6
Vintriptol 50 2c 35 6± 6 0/5
aSignificantly different from control tumours, P <0.01. bLeu-doxorubicin better effective than doxorubicin, P<0.01. CVinblastine-leu or vintriptol less effective than vinblastine, P<0.01.1046 E. BOVEN et al.
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Figure 1 Treatment results of doxorubicin 8 mgkg-' i.v. x 2 (A) and leu-doxorubicin 28 mg kg-' i.v. (l) in four human ovarian
cancer xenografts, as compared to control tumours (l). The relative tumour volume is the tumour volume at any given day VT/ the volume at the start of treatment VO. The graphs are drawn from the mean (± s.e.m.) of the relative tumour volumes.
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Figure 2 Treatment results of vinblastine 6 mg kg- ' i.v. x 2 (*), vinblastine-leu 12 mg kg- ' i.v. x 2 (U) and vintriptol 50 mg kg- '
i.v. x 2 (A) in two human ovarian cancer xenografts, as compared to control tumours (-). The relative tumour volume is the
tumour volume at any given day VT/ the volume at the start of treatment VO. The gaps are drawn from the mean (± s.e.m.) of the relative tumour volumes.
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kemia grown s.c. in mice leu-doxorubicin was superior to
doxorubicin as expressed by the considerable increase in
life-span (Baurain et al., 1980). These promising characteris-
tics led to extensive efforts to elucidate the mechanism of
prodrug activation. Cellular pharmacology of leu-doxo-
rubicin indicated hydrolytic enzymes found within lysosomes,
such as cathepsin B and N-acetyl-i-glucosaminidase, to be
responsible for the release of active drug (Masquelier et al.,
1980b).
At equitoxic doses in human tumour-bearing nude mice,
leu-doxorubicin could be given in a 3-fold higher dose than
doxorubicin and was found again better effective than the
parent compound. This suggests, that human tumour tissue
may be the major site for activation of this prodrug. Hydro-
lytic enzymes known to occur in high concentrations in
human tumour cells are cathepsins. These cysteine proteases
can be measured in tissue cytosol and elevated concentrations
have been correlated with malignancy or even prognosis
(Maciewicz et al., 1989; Thorpe et al., 1989). Cell death or
secretion of these proteases may result in enzyme activity in
the pericellular space. Recently, leu-doxorubicin has entered
clinical trials in cancer patients and the MTD was indeed
3-fold higher than that of the parent compound (Tresca et
al., 1991). The amount of free drug in the circulation after
leu-doxorubicin administration to patients was 4-fold lower
than for an equimolar dose of the parent compound (De
Jong et al., 1991).
From the vinblastine-23-oyl amino acid derivatives, both
vinblastine-leu and vintriptol were found to induce a higher
increase in life-span of mice implanted i.v. with P388 or
L1210 leukaemia as compared to vinblastine (Bhushana Rao
et al., 1985). In our human ovarian cancer xenografts, how-
ever, none of the drugs was superior to vinblastine. For
vinblastine-leu, an explanation may be that only a 2-fold
higher dose than that for the parent compound could be
given. Several mechanisms may explain the differential
efficacy observed with leu-doxorubicin and vinblastine-leu in
the same human ovarian cancer xenografts, such as differ-
ences in pharmacokinetics, tumour tissue distribution, pro-
drug activation at the tumour site, or the cellular uptake rate
of the activated drugs. These questions should be addressed
in further experiments to gain better insight in the potential
clinical value of leucyl derivatives for use as prodrugs. For
vintriptol, a recent phase I clinical trial showed that
myelosuppression was the dose-limiting factor, rather than
neurotoxicity (Oosterkamp et al., 1991). Unfortunately,
preliminary data from a broad phase II trial have not indi-
cated tumour types to be responsive to the drug (Ten Bokkel
Huinink et al., 1990).
The development of prodrugs of conventional cytostatic
agents remains an interesting area in the search of anti-
cancer drugs with a higher therapeutic index. Human tumour
xenografts may add valuable information on the anti-tumour
activity of these prodrugs to be expected in the clinic. In this
respect, a phase II trial in ovarian cancer patients is awaited
to demonstrate the potential superiority of leu-doxorubicin in
terms of improvement of efficacy and reduction of cardio-
toxicity.
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